Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2596 to 2610 of 8213 results

  1. Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]: final draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 21 January 2026.

    Technology appraisal guidance
    In consultation

  2. Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]

    In development Reference number: GID-TA11058 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]

    In development Reference number: GID-TA10726 Expected publication date:  13 May 2026

    Technology appraisal guidance
    In development

  4. Neonatal infection: antibiotics for prevention and treatment - update

    In development Reference number: GID-NG10456 Expected publication date:  13 May 2026

    NICE guideline
    In development

  5. Perioperative care in adults

    In development Reference number: GID-QS10094 Expected publication date:  01 July 2026

    Quality standard
    In development

  6. Port Delivery platform with ranibizumab for treating wet age-related macular degeneration [ID3983]

    Awaiting development Reference number: GID-TA10879 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 30 January 2026.

    Technology appraisal guidance
    In consultation

  8. Perioperative care in adults: quality standard consultation

    We are listening to your views on this Quality standard. Comments close 6 February 2026.

    Quality standard
    In consultation

  9. Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

    In development Reference number: GID-TA10575 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]

    In development Reference number: GID-TA11498 Expected publication date:  29 April 2026

    Technology appraisal guidance
    In development

  11. Off-pump minimal access mitral valve repair by artificial chordae insertion to treat mitral regurgitation

    In development Reference number: GID-IPG10216 Expected publication date:  25 February 2026

    Interventional procedures guidance
    In development

  12. Technologies to support self-monitoring of vision change for people with macular disease (provisional title)

    In development Reference number: GID-HTE10073 Expected publication date: TBC

    Health technology evaluations
    In development

  13. Suspected sepsis in pregnancy: recognition, diagnosis and early management

    In development Reference number: GID-NG10468 Expected publication date:  17 February 2027

    NICE guideline
    In development

  14. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development Reference number: GID-TA11220 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Pharmalgen for the treatment of bee and wasp venom allergy

    In development Reference number: GID-TA11898 Expected publication date: TBC

    Technology appraisal guidance
    In development